Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PTPN1 | P18031 | 1/20 | 0.36 |
| ▸ | LMNA | P02545 | 1/20 | 0.36 |
| ▸ | CTSS | P25774 | 7/20 | 0.35 |
| ▸ | CTSK | P43235 | 5/20 | 0.35 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.35 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.34 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.34 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.34 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.34 |
| ▸ | NPC1 | O15118 | 1/20 | 0.34 |
| ▸ | TP53 | P04637 | 1/20 | 0.34 |
| ▸ | RAB9A | P51151 | 1/20 | 0.34 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.34 |
| ▸ | MAOB | P27338 | 1/20 | 0.34 |
| ▸ | ADAMTS4 | O75173 | 1/20 | 0.34 |
| ▸ | MMP13 | P45452 | 1/20 | 0.34 |
| ▸ | CTSL | P07711 | 2/20 | 0.34 |
| ▸ | CTSB | P07858 | 2/20 | 0.34 |
| ▸ | TRPA1 | O75762 | 1/20 | 0.34 |
| ▸ | GPR119 | Q8TDV5 | 1/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL30808724 | 1.00 | PTPN1 (0.36) | PTPN1LMNACTSSCTSKL3MBTL1 | |
| SCHEMBL4797998 | 1.00 | PTPN1 (0.36) | PTPN1LMNACTSSCTSKL3MBTL1 | |
| SCHEMBL3594424 | 0.81 | MEN1 (0.36) | ALDH1A1KDM4ENPSR1 | |
| SCHEMBL7014616 | 0.79 | L3MBTL1 (0.35) | L3MBTL1ALDH1A1TP53 | |
| SCHEMBL17086067 | 0.78 | ALDH1A1 (0.41) | LMNACTSSSMN1; SMN2ALDH1A1KDM4E | |
| SCHEMBL4803084 | 0.78 | KEAP1 (0.38) | — | |
| SCHEMBL7229620 | 0.78 | SMPD2 (0.41) | CTSSCTSKALDH1A1KDM4ENPC1 | |
| SCHEMBL17912379 | 0.78 | KEAP1 (0.38) | — | |
| SCHEMBL29481029 | 0.78 | KEAP1 (0.38) | — | |
| SCHEMBL1326634 | 0.78 | SMPD2 (0.41) | CTSSCTSKALDH1A1KDM4ENPC1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7425550-B2 | Lactam glycogen phosphorylase inhibitors and method of use | BRISTOL-MEYERS SQUIBB COMPANY (US) | 2008-09-16 | — | — | US | disclosed |
| US-7098235-B2 | Triglyceride and triglyceride-like prodrugs of glycogen phosphorylase inhibiting compounds | BRISTOL-MYERS SQUIBB CO. (US) | 2006-08-29 | — | — | US | disclosed |
| US-20060128687-A1 | Lactam glycogen phosphorylase inhibitors and method of use | SHER PHILIP | 2006-06-15 | — | — | US | disclosed |
| US-7057046-B2 | Lactam glycogen phosphorylase inhibitors and method of use | BRISTOL-MYERS SQUIBB COMPANY (US) | 2006-06-06 | — | — | US | disclosed |
| US-20040142938-A1 | Triglyceride and triglyceride-like prodrugs of glycogen phosphorylase inhibiting compounds | BRISTOL-MYERS SQUIBB COMPANY | 2004-07-22 | — | — | US | disclosed |
| US-20040002495-A1 | Lactam glycogen phosphorylase inhibitors and method of use | BRISTOL-MYERS SQUIBB COMPANY | 2004-01-01 | — | — | US | disclosed |
| EP-1048651-B1 | NITROGEN-CONTAINING TETRACYCLIC COMPOUNDS | TAISHO PHARMACEUTICAL CO LTD (JP) | 2003-05-14 | — | — | EP | disclosed |
| US-6281355-B1 | Nitrogen-containing tetracyclic compounds | TAISHO PHARMACEUTICAL CO., LTD. (JP) | 2001-08-28 | — | — | US | disclosed |
| EP-1048651-A1 | NITROGEN-CONTAINING TETRACYCLIC COMPOUNDS | TAISHO PHARMACEUTICAL CO., LTD (JP) | 2000-11-02 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040142938-A1 | Triglyceride and triglyceride-like prodrugs of glycogen phosphorylase inhibiting compounds | PYGL, PNLIP, PYGM | PTPN1 439/4885LMNA 492/4885CTSS 2295/4885 |
| US-20040002495-A1 | Lactam glycogen phosphorylase inhibitors and method of use | PYGL, PYGM, GYS2 | PTPN1 2476/4885LMNA 258/4885CTSS 1520/4885 |
| US-20060128687-A1 | Lactam glycogen phosphorylase inhibitors and method of use | PYGL, PYGM, GYS1 | PTPN1 946/4885LMNA 1250/4885CTSS 1182/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.